Overview

Definition:
-Typhoid fever is a systemic febrile illness caused by infection with the bacterium *Salmonella enterica* serovar Typhi (S
-Typhi)
-It is characterized by prolonged fever, headache, abdominal pain, and sometimes a rash.
Epidemiology:
-Typhoid fever is endemic in many developing countries, particularly in South Asia, Southeast Asia, and parts of Africa and Latin America
-Children are disproportionately affected due to lower levels of hygiene and sanitation
-Incidence rates can be as high as 100-300 per 100,000 population in endemic areas
-Approximately 10-20 million cases and 200,000 deaths occur annually worldwide, with children accounting for a significant proportion.
Clinical Significance:
-Typhoid fever in children poses a significant public health challenge due to its potential for severe morbidity and mortality if left untreated or if drug-resistant strains are involved
-Prompt and accurate diagnosis, appropriate antibiotic therapy, and effective prevention strategies are crucial for reducing disease burden and improving outcomes, making this a critical topic for pediatricians and those preparing for DNB and NEET SS examinations.

Clinical Presentation

Symptoms:
-Insidious onset of fever, typically gradually increasing in temperature over several days
-Relative bradycardia (pulse rate slower than expected for the degree of fever)
-Headache
-Abdominal pain, often diffuse or in the right lower quadrant
-Loss of appetite
-Constipation or diarrhea (sometimes pea-soup stools)
-Cough
-Malaise
-Rash (rose spots) may appear in about 10-15% of cases, typically on the trunk.
Signs:
-Fever (may reach 39-40°C)
-Relative bradycardia
-Abdominal tenderness, particularly on palpation of the right iliac fossa
-Hepatosplenomegaly may be present
-Neurological symptoms such as confusion, delirium, or stupor can occur in severe cases
-Rose spots: faint, rose-colored, blanching macules appearing on the abdomen and chest
-Signs of dehydration may be evident.
Diagnostic Criteria:
-There are no definitive clinical criteria for typhoid fever due to its nonspecific presentation
-Diagnosis relies on a combination of clinical suspicion, epidemiological factors, and microbiological confirmation
-However, in resource-limited settings, clinical suspicion based on prolonged fever, abdominal symptoms, and epidemiological risk is often the basis for empirical treatment
-Definitive diagnosis is based on isolation of S
-Typhi from blood, stool, urine, or bone marrow
-Serological tests like the Widal test have limited reliability for early diagnosis and are prone to false positives and negatives, especially in endemic areas.

Diagnostic Approach

History Taking:
-Detailed history of fever onset and progression
-Travel history to or residence in endemic areas
-Exposure to contaminated food or water
-Symptoms of gastrointestinal distress (abdominal pain, diarrhea, constipation)
-Associated symptoms like headache, cough, or rash
-Immunization status, particularly against typhoid vaccines
-Previous episodes of typhoid fever.
Physical Examination:
-Assess vital signs, including temperature and heart rate (looking for relative bradycardia)
-Perform a thorough abdominal examination for tenderness, distension, hepatosplenomegaly, and bowel sounds
-Examine the skin for characteristic rose spots
-Assess hydration status and for signs of neurological involvement.
Investigations:
-Blood culture: Gold standard for diagnosis, positive in 50-70% of cases in the first week of illness, decreasing thereafter
-Stool culture: Can be positive from the second week onwards, becoming more sensitive as illness progresses
-Urine culture: Less sensitive but can be positive
-Bone marrow culture: Highly sensitive (90-95%), especially in prolonged or complicated cases, but invasive
-Complete blood count (CBC) may show leukopenia with a left shift, anemia, and thrombopenia
-Liver function tests may show mild elevation
-Polymerase chain reaction (PCR) for S
-Typhi DNA is a rapid diagnostic method but is not widely available
-Serological tests (Widal test): Often used but has low specificity and sensitivity, especially in endemic regions and with prior vaccination
-Typhidot (IgM and IgG antibodies against OMP) is more specific but can have varying sensitivity.
Differential Diagnosis:
-Other febrile illnesses with gastrointestinal symptoms, such as malaria, dengue fever, viral gastroenteritis, bacterial gastroenteritis (e.g., *Salmonella Paratyphi*, *Shigella*, *Campylobacter*), tuberculosis, viral hepatitis, rickettsial infections, and brucellosis
-Non-infectious causes of fever and abdominal pain should also be considered.

Management

Initial Management:
-Prompt initiation of appropriate antibiotic therapy based on local resistance patterns
-Adequate hydration and nutritional support
-Monitoring for complications
-Isolation of the patient to prevent further transmission.
Medical Management:
-Antibiotic therapy is the mainstay of treatment
-Choice depends on local susceptibility patterns
-- First-line agents (where susceptible): - Azithromycin: 10-20 mg/kg/day once daily for 7-14 days (oral or IV)
-Commonly used in children due to good efficacy and favorable safety profile
-- Ceftriaxone: 50-100 mg/kg/day IV in 1-2 divided doses for 7-14 days
-Effective for severe infections and parenteral use
-- Alternative agents (for multidrug-resistant strains or allergies): - Ciprofloxacin or Levofloxacin (fluoroquinolones): Generally avoided in children under 8 years due to concerns about cartilage damage, but may be used in severe cases in older children or if no alternatives exist (e.g., 10-15 mg/kg/day IV or PO for 10-14 days)
-- Trimethoprim-sulfamethoxazole (TMP-SMX): 8-10 mg/kg/day (TMP component) divided into 2 doses for 14 days
-May be used if susceptible
-- Duration of treatment: Typically 7-14 days
-Shorter courses (e.g., 5-7 days with azithromycin) are being evaluated
-- Treatment of asymptomatic carriers: Usually involves fluoroquinolones or TMP-SMX for longer durations (e.g., 4-6 weeks), but this is less common in children
-*Dosage adjustments may be needed for renal or hepatic impairment.*
Surgical Management:
-Rarely indicated
-Primarily for complications such as intestinal perforation, hemorrhage, or toxic megacolon
-Management is surgical resection and repair, often with broad-spectrum antibiotics and intensive supportive care.
Supportive Care:
-Fluid and electrolyte management is crucial, especially in cases of diarrhea or vomiting
-Oral rehydration solution (ORS) for mild to moderate dehydration
-Intravenous fluids (e.g., Ringer's lactate, normal saline) for severe dehydration or inability to tolerate oral intake
-Nutritional support: Maintain adequate caloric intake
-bland, easily digestible diet
-Antipyretics (e.g., paracetamol) for fever
-Careful monitoring for complications such as intestinal perforation, hemorrhage, encephalitis, or sepsis
-Antiemetics may be used for nausea and vomiting.

Complications

Early Complications:
-Intestinal perforation: Occurs in 1-3% of cases, typically in the third or fourth week of illness, most commonly at the ileocecal junction
-Presents with sudden onset of severe abdominal pain, fever, vomiting, and signs of peritonitis
-Intestinal hemorrhage: Can occur from Peyer's patches, presenting as melena or hematochezia
-Encephalitis: Neurological manifestations like delirium, stupor, coma, seizures, and focal neurological deficits.
Late Complications:
-Relapse: Occurs in 5-10% of patients, usually 1-2 weeks after defervescence, with similar symptoms
-Sepsis: Disseminated infection leading to multi-organ failure
-Abscesses: Formation of abscesses in the liver, spleen, or bone
-Cholecystitis or cholangitis
-Chronic carrier state: Persistent shedding of S
-Typhi in feces or urine, more common in adults but can occur in children who have had severe disease
-Osteomyelitis or endocarditis (rare).
Prevention Strategies:
-Improved sanitation and access to clean water are the most effective long-term prevention strategies
-- Vaccination: - Vi polysaccharide vaccine (ViPS): Licensed for children >2 years old, provides moderate protection
-Requires booster doses
-- Conjugate vaccines (e.g., Vi-TT, Vi-PS-rEPA): Licensed for infants and children from 6 months to <2 years old
-Generally offer better and longer-lasting immunity
-Recommended for children in endemic areas or traveling to such regions
-- Food and water safety: Educate communities on safe food handling practices, proper cooking, and avoiding raw or undercooked foods and contaminated water
-- Personal hygiene: Emphasis on regular handwashing, especially after defecation and before meals.

Prognosis

Factors Affecting Prognosis:
-Timeliness and adequacy of antibiotic treatment
-Strain virulence and antibiotic susceptibility
-Presence of complications (e.g., perforation, sepsis)
-Nutritional status and immune status of the child
-Age (infants and young children have a higher risk of severe disease).
Outcomes:
-With appropriate antibiotic treatment, mortality rates are low (<1%)
-However, in untreated cases or those with complications, mortality can be significant (10-30%)
-Children who survive may experience a carrier state or sequelae from severe disease
-Prompt and effective management leads to complete recovery in most cases.
Follow Up:
-Children treated for typhoid fever should have follow-up to ensure complete recovery and monitor for relapses or complications
-Stool cultures may be recommended a few weeks after treatment to assess for clearance of the organism
-Education on preventive measures for the child and family is essential.

Key Points

Exam Focus:
-Diagnosis of typhoid fever in children relies on clinical suspicion combined with microbiological confirmation
-Blood culture is the gold standard for early diagnosis
-Antibiotic choice for children is guided by local resistance patterns, with azithromycin and ceftriaxone being common choices
-Relative bradycardia and rose spots are classic but not always present findings
-Prevention through vaccination and improved sanitation is paramount.
Clinical Pearls:
-Always consider typhoid fever in a febrile child from or returning from an endemic area, even with nonspecific symptoms
-Remember to check for relative bradycardia, which is a key differentiator
-In resource-limited settings, do not delay empirical antibiotic treatment based on clinical suspicion if microbiological confirmation is unavailable
-Be vigilant for complications, especially intestinal perforation, which is a surgical emergency
-Recognize the importance of local antibiotic resistance patterns when choosing therapy.
Common Mistakes:
-Over-reliance on Widal test for diagnosis, especially in endemic areas where false positives are common
-Delaying treatment while awaiting definitive culture results in critically ill children
-Using inappropriate antibiotics for multidrug-resistant strains
-Underestimating the importance of supportive care and hydration
-Neglecting to counsel families on preventive measures, leading to recurrent infections.